Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by prophetoffactzon Jan 20, 2023 11:43am
131 Views
Post# 35235638

RE:RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

RE:RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR"Md got a heck of a lot more done than DR"

Incredibly hard to argue that.

Rathjen's Chiesi deal beats Day's Prothena deal.

Rathjen delivered more deals and evaluations(Chiesi, J&J, Neuramedy, Daiichi, Oxyrane, Aposense, and potentially Ellipses) than Day(Prothena, undisclosed major pharma).  

Rathjen dellvered more transformational deals(Cresence, Biodexa).

Day failed to advance xB3 into the clinic as Rathjen, and put BTI in a financial mess as Rathjen but atleast Rathjen has the balls to address the disaster and put the company on a viable path with the Biodexa deal and potential US$20 million in financing. Rathjen may finally get BTI on NASDAQ too which Day failed to do. Biodexa also significantly strengthens BTI with scale, resources, and complementary assets. Biodexa could have the backing on important fund like Armistice Capital as a major shareholder. Day didn't deliver one major backer like this. If Day had the force of character to correct BTI's course as Rathjen is now demonstrating BTI could be in a much healthier place today.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities